FUJIFILM Diosynth Biotechnologies Newsletter – March 2024
FUJIFILM Diosynth Biotechnologies
Partners for Life, Advancing Tomorrow's Medicines
We announced that we had entered into a ten-year renewable energy power purchase agreement with Better Energy for our Hiller?d, Denmark manufacturing site. This agreement completes an important aspect of our climate strategy, Partners for the Planet.?
As part of our commitment to fostering a sustainable future, we launched a new area of our website that communicates how we are integrating environmental, social, and governance principles into our operations to make a positive impact on the world.??
We are pleased to introduce the first flexible cell culture facility utilizing our KojoX? modular design concepts. This single-use cell culture facility in Billingham, UK, is scheduled to be operational by 2026.?
We are delighted to introduce our groundbreaking strategy aimed at revolutionizing the customer experience landscape. At the heart of our approach lie three fundamental pillars: People First, Transforming the Industry, and Unprecedented Delivery.?
?
Creating effective, scalable manufacturing strategies for adeno-associated virus (AAV) therapies means sponsors and CDMOs must identify creative and collaborative solutions in the early phases of development. In a recent webinar, our Director of CMC Program Design, Ian Goodwin, provided his expert insight into the benefits of implementing early-phase studies like candidate screening and feasibility assessments for AAV manufacturing.??
In response to recent revisions to the European Commission’s Annex 1 regulatory framework, many CDMOs are scrambling to retrofit their drug product fill lines with innovative technology that meets new environmental monitoring standards. In contrast, we share the benefits of partnering with a CDMO whose drug product fill lines were built to fulfill Annex 1 standards and reduce potential contamination risks from the start.?
Biopharmaceutical shortages continue to be a concern across the globe. If faced with uncertain demand forecasts, a CDMO that offers a modular approach to manufacturing as well as the ability to shift between continuous and large-scale manufacturing as needed will help you mitigate production disruptions and ensure patient access to your therapeutic.?
领英推荐
In this on-demand webinar, learn what FUJIFILM Diosynth Biotechnologies can offer in the rare disease space, in terms of strategies to expedite workflows, internalize critical reagents, and standardize facilities and equipment.?
Outsourced Pharma Capacity Updates?
Catch up on our expert contributions to recent capacity update webinars with Outsourced Pharma.
Upcoming Events?
March 18-21, New York City, NY?
DCAT Week is here, and we look forward to conducting strategic and collaborative meetings with many of our partners next week. If you have not yet booked time with us, you can request a meeting here.?
March 19-20, London?
We are proud to be a platinum sponsor at Advanced Therapies at ExCel, London. Schedule a meeting via the meeting app or stop by booth #10 to learn more about how we can help you advance and deliver tomorrow’s medicines. We also invite you to attend our keynote presentation at 10:10am on March 20, where Michael Baker, Senior Director Viral Gene Therapy, will speak on?the future of Advanced Therapies from a CDMO’s perspective.?
?
March 25-27, Long Beach, CA?
As part of our participation in the PDA Annual Meeting, our Director of Global Alliance Management, Morten Munk, will moderate the P2 session: ‘It All Starts with Selecting the Right Collaboration Partner’. This session will introduce the importance of selecting the right partner for your project, following the decision to outsource.?